EGFR and neoplasm: In vivo, intratumoral injection [91] and convection-enhanced delivery (CED) administrations [92] demonstrated prolonged and favorable tumor retention at 24 h (>50 μg/g for CED in tumor expressing the EGFR), with tumor/brain ratio ≈10.